AlphAIAlphAI — Financial news for AI agents
tradingview.com$NXGL

NXGL Q3'26 Earnings: revenue estimate is 4.19M USD

NexGel (NXGL) plans to release Q3'26 earnings on November 17. Analysts expect revenue of 4.19M USD and an EPS of (4.80) USD. The announcement is scheduled for 7:00 AM ET (12:00 PM UTC).

Original reporting
tradingview.com
Published Nov 10, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 12:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
NXGL Q3'26 Earnings: revenue estimate is 4.19M USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$NXGLNeutralLow
01

Why it matters

The preview estimate sets market expectations; actual results will determine price direction.

02

Market read

Limited relevance due to small market cap and modest revenue forecast; primarily of interest to niche investors.

03

What to watch

Potential upcoming partnership announcements or regulatory news not mentioned could amplify price movement.

Relevance 5/10Novelty 5/10Timing: pre‑market on Nov 17

Background

NexGel, Inc. (NXGL) is a micro‑cap listed on a US exchange, scheduled to release its Q3'26 earnings on Nov 17.

Company-level read

Ticker impact

$NXGLNeutralMedium confidence
Context

Article provides the first public revenue and EPS estimate for NexGel's Q3'26 earnings scheduled on Nov 17.

Expected impact

likely limited pressure as investors await actual numbers; potential slight downside if results miss the $4.19M estimate.

Evidence & confidence

Micro‑cap with low absolute figures; estimate alone rarely moves price dramatically.

Market effects

Sector

Minimal impact on the broader biotech/tech sector due to the company's small size.

Regional

Negligible effect on US markets; limited regional relevance.

Global

None

Counterpoint

What could challenge this read

If the estimate is overly conservative, a surprise beat could trigger a short‑squeeze in this thinly‑traded stock.

Key entities

  • company
    NexGel, Inc.

    US‑listed micro‑cap providing biotech/tech solutions.

Read at source← All news

Related articles

$NXGLMed

NexGel secures 95% noteholder support for debt conversion

NEXGEL, Inc. (NASDAQ: NXGL) announced that 95% of its convertible noteholders, representing $14.125 million, agreed to convert notes into common stock, contingent on a strategic merger and other conditions. The company has secured $1.2 million in commitments, with Sequence LifeScience contributing 61%. NXGL is pursuing cost savings and a potential merger with Fountainhead LifeSciences, with a deadline of March 31, 2027.

investing.com
$NXGLLow

NEXGEL Reports Second Quarter 2026 Financial Results

NEXGEL, INC. (NXGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEXGEL Reports Second Quarter 2026 Financial Results LANGHORNE, Pa. – August 17, 2026 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content

SEC EDGAR 8-K
$INKTHigh

MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H…

MiNK Therapeutics, Inc. (INKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies November 11, 2026 & Patients with serious unmet medical need access agenT-797 through phy

SEC EDGAR 8-K